miDiagnostics–SEVERAL: investment, 202412 financing round Series D €30m led by Thermo Fisher Scientific

	Period	2024-12-04
	Money taker	miDiagnostics N.V.
	Money source	SEVERAL
	Product	real-time PCR technology
	Product 2	venture capital
	Person	Vandeurzen, Urbain (Gimv 201302 Chairman of Board of Directors)

miDiagnostics N.V.. (12/4/24). "Press Release: miDiagnostics Secures €30 Million Series D Funding Round Led by Thermo Fisher Scientific to Advance an Innovative Sterility Test and Other Quality Control Tests for use in the BioPharma Industry". Leuven.

miDiagnostics is pleased to announce the completion of a €30 million Series D funding round, led by Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science. This investment will accelerate the development of a groundbreaking sterility test for batch release and related quality control tests for the BioPharma Industry, utilizing miDiagnostics’ proprietary qPCR technology.

The Series D round is further strengthened by the continued support of current investors Alychlo, VMF Invest and Pamica, who share a vision for the future of healthcare technology.

“Our continued investment in miDiagnostics reflects our confidence in their vision and the transformative potential of their technology. We believe that with the support of Thermo Fisher Scientific, miDiagnostics is well-capitalized to make significant strides in improving healthcare outcomes,” said Urbain Vandeurzen, corner stone Investor and Chairman of miDiagnostics.

“We are thrilled to have the support of Thermo Fisher Scientific as we advance our mission to revolutionize sterility testing in the biopharma sector,” said Katleen Verleysen, CEO of miDiagnostics. “This funding will enable us to expedite our development efforts and leverage Thermo Fisher’s expertise for the commercialization of our pioneering products.”

“Our investment in miDiagnostics underscores its innovative approach to sterility testing and the potential it could have on enhancing patient safety and outcomes for the biopharma industry. This is well aligned with our Mission to enable our customers to make the world healthier, cleaner and safer,” said Bhooshi De Silva, head of strategic capital, Thermo Fisher Scientific.

For more information, please contact:

Katleen Verleysen, PhD
CEO
Gaston Geenslaan 1
B-3001 Leuven, Belgium
[email protected]

About miDiagnostics

miDiagnostics is at the forefront of advancing healthcare through innovative silicon chip technology, delivering miniaturized, rapid, and user-friendly lab-quality tests directly to patients and clinicians. By integrating a nanofluidic processor on a chip with a compact reader, miDiagnostics is capable of measuring a wide array of biomarkers from minimally invasive samples.

Aligned with our mission to enhance the safety and efficacy of various therapies, we are committed to providing reliable and innovative sterility testing and other quality assurance services that empower biopharmaceutical companies. This commitment ensures compliance with the highest industry standards and fosters trust in advanced therapeutic solutions.